Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

Angiogenesis PET Tracer Uptake (68Ga-NODAGA-E[(cRGDyK)]₂) in Induced Myocardial Infarction and Stromal Cell Treatment in Minipigs.

Rasmussen T, Follin B, Kastrup J, Brandt-Larsen M, Madsen J, Emil Christensen T, Juhl M, Cohen S, Pharao Hammelev K, Holdflod Møller C, Peter Goetze J, Hasbak P, Kjær A.

Diagnostics (Basel). 2018 May 16;8(2). pii: E33. doi: 10.3390/diagnostics8020033.

2.

Use of risk-adjusted CUSUM charts to monitor 30-day mortality in Danish hospitals.

Rasmussen TB, Ulrichsen SP, Nørgaard M.

Clin Epidemiol. 2018 Apr 18;10:445-456. doi: 10.2147/CLEP.S157162. eCollection 2018.

3.

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.

Rasmussen TA, McMahon JH, Chang JJ, Audsley J, Rhodes A, Tennakoon S, Dantanarayana A, Spelman T, Schmidt T, Kent SJ, Morcilla V, Palmer S, Elliott JH, Lewin SR.

Lancet HIV. 2018 May;5(5):e221-e230. doi: 10.1016/S2352-3018(18)30040-7. Epub 2018 Apr 8.

PMID:
29643011
4.

Full-length genome sequences of porcine epidemic diarrhoea virus strain CV777; Use of NGS to analyse genomic and sub-genomic RNAs.

Rasmussen TB, Boniotti MB, Papetti A, Grasland B, Frossard JP, Dastjerdi A, Hulst M, Hanke D, Pohlmann A, Blome S, van der Poel WHM, Steinbach F, Blanchard Y, Lavazza A, Bøtner A, Belsham GJ.

PLoS One. 2018 Mar 1;13(3):e0193682. doi: 10.1371/journal.pone.0193682. eCollection 2018.

5.

Patient-reported outcomes in daily clinical practise in HIV outpatient care.

Kjær ASHK, Rasmussen TA, Hjollund NH, Rodkjaer LO, Storgaard M.

Int J Infect Dis. 2018 Apr;69:108-114. doi: 10.1016/j.ijid.2018.02.015. Epub 2018 Feb 21.

6.

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses.

Brinkmann CR, Højen JF, Rasmussen TA, Kjær AS, Olesen R, Denton PW, Østergaard L, Ouyang Z, Lichterfeld M, Yu X, Søgaard OS, Dinarello C, Tolstrup M.

mSphere. 2018 Feb 14;3(1). pii: e00616-17. doi: 10.1128/mSphere.00616-17. eCollection 2018 Jan-Feb.

7.

Correction to: Industrial antifoam agents impair ethanol fermentation and induce stress responses in yeast cells.

Nielsen JC, Lino FSO, Rasmussen TG, Thykær J, Workman CT, Basso TO.

Appl Microbiol Biotechnol. 2018 Jan;102(1):513. doi: 10.1007/s00253-017-8643-4.

8.

Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Pinkevych M, Fennessey CM, Cromer D, Tolstrup M, Søgaard OS, Rasmussen TA, Keele BF, Davenport MP.

J Virol. 2018 Jan 2;92(2). pii: e01667-17. doi: 10.1128/JVI.01667-17. Print 2018 Jan 15.

PMID:
29118123
9.

Transmission of African swine fever virus from infected pigs by direct contact and aerosol routes.

Olesen AS, Lohse L, Boklund A, Halasa T, Gallardo C, Pejsak Z, Belsham GJ, Rasmussen TB, Bøtner A.

Vet Microbiol. 2017 Nov;211:92-102. doi: 10.1016/j.vetmic.2017.10.004. Epub 2017 Oct 4.

PMID:
29102127
10.

Distinct roles for the IIId2 sub-domain in pestivirus and picornavirus internal ribosome entry sites.

Willcocks MM, Zaini S, Chamond N, Ulryck N, Allouche D, Rajagopalan N, Davids NA, Fahnøe U, Hadsbjerg J, Rasmussen TB, Roberts LO, Sargueil B, Belsham GJ, Locker N.

Nucleic Acids Res. 2017 Dec 15;45(22):13016-13028. doi: 10.1093/nar/gkx991.

11.

Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?

Cromer D, Pinkevych M, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP.

J Virol. 2017 Nov 30;91(24). pii: e01395-17. doi: 10.1128/JVI.01395-17. Print 2017 Dec 15.

PMID:
29021399
12.

Industrial antifoam agents impair ethanol fermentation and induce stress responses in yeast cells.

Nielsen JC, Senne de Oliveira Lino F, Rasmussen TG, Thykær J, Workman CT, Basso TO.

Appl Microbiol Biotechnol. 2017 Nov;101(22):8237-8248. doi: 10.1007/s00253-017-8548-2. Epub 2017 Oct 10. Erratum in: Appl Microbiol Biotechnol. 2017 Nov 25;:.

13.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.

JCI Insight. 2017 Aug 17;2(16). pii: 92901. doi: 10.1172/jci.insight.92901. [Epub ahead of print]

14.

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Østergaard L, Søgaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport MP, Emery S, Amin J, Cooper DA, Kan VL, Fox J, Gruell H, Parsons MS, Kent SJ.

J Virol. 2017 Jul 12;91(15). pii: e00603-17. doi: 10.1128/JVI.00603-17. Print 2017 Aug 1.

15.

Considering built environment and spatial correlation in modeling pedestrian injury severity.

Prato CG, Kaplan S, Patrier A, Rasmussen TK.

Traffic Inj Prev. 2018 Jan 2;19(1):88-93. doi: 10.1080/15389588.2017.1329535. Epub 2017 May 23.

PMID:
28534647
16.

Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.

Rasmussen TA, McMahon J, Chang JJ, Symons J, Roche M, Dantanarayana A, Okoye A, Hiener B, Palmer S, Lee WS, Kent SJ, Van Der Weyden C, Prince HM, Cameron PU, Lewin SR.

AIDS. 2017 Aug 24;31(13):1839-1845. doi: 10.1097/QAD.0000000000001540.

PMID:
28514279
17.

Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals.

Koelsch KK, Rasmussen TA, Hey-Nguyen WJ, Pearson C, Xu Y, Bailey M, Marks KH, Sasson SC, Taylor MS, Tantau R, Obeid S, Milner B, Morrissey O, Pinto AN, Suzuki K, Busch MP, Keating SM, Kaiser P, Yukl S, Wong JK, Hiener BM, Palmer S, Zaunders J, Post JJ, Chan DJ, Avery S, Milliken ST, Kelleher AD, Lewin SR, Cooper DA.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):328-337. doi: 10.1097/QAI.0000000000001381.

PMID:
28350553
18.

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Vibholm L, Schleimann MH, Højen JF, Benfield T, Offersen R, Rasmussen K, Olesen R, Dige A, Agnholt J, Grau J, Buzon M, Wittig B, Lichterfeld M, Petersen AM, Deng X, Abdel-Mohsen M, Pillai SK, Rutsaert S, Trypsteen W, De Spiegelaere W, Vandekerchove L, Østergaard L, Rasmussen TA, Denton PW, Tolstrup M, Søgaard OS.

Clin Infect Dis. 2017 Jun 15;64(12):1686-1695. doi: 10.1093/cid/cix201.

PMID:
28329286
19.

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.

Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DFJ, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR.

AIDS. 2017 May 15;31(8):1137-1141. doi: 10.1097/QAD.0000000000001442.

20.

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.

Winckelmann A, Barton K, Hiener B, Schlub TE, Shao W, Rasmussen TA, Østergaard L, Søgaard OS, Tolstrup M, Palmer S.

AIDS. 2017 Mar 27;31(6):771-779. doi: 10.1097/QAD.0000000000001400.

Supplemental Content

Loading ...
Support Center